洛克菲勒基金会、ACCESS Health发布权威报告,微医等中国经验被推向全球

2020-10-05 佚名 动脉网

国际知名基金会洛克菲勒基金会联合ACCESS Heath International(下简称“ACCESS Health”)发布了题为《数字技术和公共卫生合力应对新冠肺炎疫情:

国际知名基金会洛克菲勒基金会联合ACCESS Heath International(下简称“ACCESS Health”)发布了题为《数字技术和公共卫生合力应对新冠肺炎疫情:将中国经验带给全球》的研究报告,全面展示了六类疫情应对措施中数字科技所带来的影响。来自微医、阿里、京东等十二个中国的数字战疫案例入选,作为中国利用数字健康技术应对新冠肺炎疫情的重要经验,帮助全球各国提高疫情应对策略的有效性。

数字技术的应用对中国成功应对新冠疫情起着至关重要的作用。据了解,报告展示了在2020年初新冠肺炎疫情防控过程中,数字健康企业通过发挥自身优势,在快速反应、流行病学研究、诊断和治疗、支持性活动、长期管理、综合疾病控制体系等六方面的应对措施,并分析了其产生的深远影响。

作为疫情期间最早利用数字技术开辟抗疫“空中战场”的企业机构之一,微医被作为代表性案例收录,报告详细介绍了微医在抗疫各个阶段、不同场景下针对行业和公众的专业信息获取、医疗人员协同、在线问诊、慢病管理、基层疫情防控等医疗健康需求推出的多种解决方案。

在疫情暴发初期,微医上线“新冠肺炎实时救助平台”,为武汉和全国人民提供免费的问诊和咨询服务,分流患者,筛查轻症,减少患者赴医过程中的交叉感染风险,并先后推出“心理援助专区”、“中医药抗击疫情平台”、“全球抗疫平台”等服务。截至8月底,微医新冠肺炎实时救助平台已累计提供免费服务216万人次,总访问量超1.5亿次,单日最高访问人次超过1100万;微医全球抗疫平台获得中国170多个驻外使领馆推介,为220多个国家和地区的326万人提供防疫服务。

面向慢性病患者的复诊购药需求,微医互联网总医院为部分常见病、慢性病患者提供了在线复诊、药品配送服务。同时,在天津、泰安、武汉、济南等地相继开通医保在线支付,让用户足不出户就可以完成在线复诊和购药,享受一站式的医疗健康服务,为中国数字健康行业发展带来了重要突破。在线下,则通过包含了7大类53小项检查检验项目和100种疾病的标准化诊疗系统的“微医流动医院”,协助各地开展高效的疫情防控工作。目前,有80多辆微医流动医院在甘肃、河南、宁夏、湖北等地投入服务。

报告指出,微医在此次新冠肺炎疫情防控中快速反应、高效调动协调资源等能力,凸显了平台型互联网医院的独特价值。微医已经打磨出一个覆盖医、药、检、数、保的数字平台,推动了医疗健康服务要素的深度融合和服务闭环的完善,构建了一个新型的健康保障服务体系,使其在面对突发的危机时,能够快速、充分地利用数字健康平台与政府、医疗机构及多方合作伙伴进行有效协作,做到服务质量、效率和体验的提升。

报告发布会上,洛克菲勒基金会联合ACCESS Health、耶鲁大学公共卫生学院举办了一场线上圆桌论坛,世界卫生组织首席科学家Soumya Swaminathan博士,洛克菲勒基金会高级副总裁Naveen Rao博士,耶鲁大学公共卫生学院院长Sten Vermund博士,ACCESS Health主席兼总裁、中美健康峰会理事长William A Haseltine博士等全球重要的意见领袖、公共卫生专家、研究人员和医疗从业人员,共同讨论了如何扩大“数字抗疫”的影响,并利用数字健康解决方案增强应对全球危机的能力。

洛克菲勒基金会亚洲区董事总经理Deepali Khanna认为:“大量疫情应对策略指出,将大数据、数字健康技术纳入公共卫生系统和应急应对系统是一项至关重要的任务。”未来,数字健康将有力地促进和推动全球健康产业数字化升级,更好地服务世界各国民众的健康需求。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1779301, encodeId=e74d1e7930180, content=<a href='/topic/show?id=a068181685' target=_blank style='color:#2F92EE;'>#ACCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1816, encryptionId=a068181685, topicName=ACCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Aug 19 07:39:38 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778925, encodeId=a80d1e78925ad, content=<a href='/topic/show?id=a068181685' target=_blank style='color:#2F92EE;'>#ACCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1816, encryptionId=a068181685, topicName=ACCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu May 06 21:39:38 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861407, encodeId=4b65186140ec3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Jun 07 22:39:38 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326710, encodeId=60001326e1009, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 07 14:39:38 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621873, encodeId=de6f16218e31d, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Wed Oct 07 14:39:38 CST 2020, time=2020-10-07, status=1, ipAttribution=)]
    2021-08-19 hxj0117
  2. [GetPortalCommentsPageByObjectIdResponse(id=1779301, encodeId=e74d1e7930180, content=<a href='/topic/show?id=a068181685' target=_blank style='color:#2F92EE;'>#ACCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1816, encryptionId=a068181685, topicName=ACCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Aug 19 07:39:38 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778925, encodeId=a80d1e78925ad, content=<a href='/topic/show?id=a068181685' target=_blank style='color:#2F92EE;'>#ACCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1816, encryptionId=a068181685, topicName=ACCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu May 06 21:39:38 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861407, encodeId=4b65186140ec3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Jun 07 22:39:38 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326710, encodeId=60001326e1009, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 07 14:39:38 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621873, encodeId=de6f16218e31d, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Wed Oct 07 14:39:38 CST 2020, time=2020-10-07, status=1, ipAttribution=)]
    2021-05-06 hxj0117
  3. [GetPortalCommentsPageByObjectIdResponse(id=1779301, encodeId=e74d1e7930180, content=<a href='/topic/show?id=a068181685' target=_blank style='color:#2F92EE;'>#ACCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1816, encryptionId=a068181685, topicName=ACCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Aug 19 07:39:38 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778925, encodeId=a80d1e78925ad, content=<a href='/topic/show?id=a068181685' target=_blank style='color:#2F92EE;'>#ACCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1816, encryptionId=a068181685, topicName=ACCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu May 06 21:39:38 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861407, encodeId=4b65186140ec3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Jun 07 22:39:38 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326710, encodeId=60001326e1009, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 07 14:39:38 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621873, encodeId=de6f16218e31d, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Wed Oct 07 14:39:38 CST 2020, time=2020-10-07, status=1, ipAttribution=)]
    2021-06-07 shizhenshan
  4. [GetPortalCommentsPageByObjectIdResponse(id=1779301, encodeId=e74d1e7930180, content=<a href='/topic/show?id=a068181685' target=_blank style='color:#2F92EE;'>#ACCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1816, encryptionId=a068181685, topicName=ACCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Aug 19 07:39:38 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778925, encodeId=a80d1e78925ad, content=<a href='/topic/show?id=a068181685' target=_blank style='color:#2F92EE;'>#ACCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1816, encryptionId=a068181685, topicName=ACCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu May 06 21:39:38 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861407, encodeId=4b65186140ec3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Jun 07 22:39:38 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326710, encodeId=60001326e1009, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 07 14:39:38 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621873, encodeId=de6f16218e31d, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Wed Oct 07 14:39:38 CST 2020, time=2020-10-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1779301, encodeId=e74d1e7930180, content=<a href='/topic/show?id=a068181685' target=_blank style='color:#2F92EE;'>#ACCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1816, encryptionId=a068181685, topicName=ACCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu Aug 19 07:39:38 CST 2021, time=2021-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778925, encodeId=a80d1e78925ad, content=<a href='/topic/show?id=a068181685' target=_blank style='color:#2F92EE;'>#ACCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1816, encryptionId=a068181685, topicName=ACCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ac59108, createdName=hxj0117, createdTime=Thu May 06 21:39:38 CST 2021, time=2021-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861407, encodeId=4b65186140ec3, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Mon Jun 07 22:39:38 CST 2021, time=2021-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326710, encodeId=60001326e1009, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Wed Oct 07 14:39:38 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621873, encodeId=de6f16218e31d, content=<a href='/topic/show?id=5f1386329e' target=_blank style='color:#2F92EE;'>#Health#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=17, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8632, encryptionId=5f1386329e, topicName=Health)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8d2020283215, createdName=yyanpro@28cn.c, createdTime=Wed Oct 07 14:39:38 CST 2020, time=2020-10-07, status=1, ipAttribution=)]

相关资讯

中国经验成为世卫消除疟疾技术策略

日内瓦时间5月22日,中国和斯里兰卡、缅甸共同举办的“努力实现全民健康覆盖——国家主导的消除疟疾行动”主题边会在世卫大会期间召开。中国国家卫生健康委员会崔丽副主任出席边会并做主旨发言。

外媒聚焦中国防控成效:“中国经验”效果明显

当前,中国新冠肺炎疫情防控形势持续向好,生产生活秩序正加速重回轨道。连日来,国际主流媒体持续报道中国疫情防控新形势。中国积极、有效的防治措施获得国际专家赞扬,“中国经验”也给其